亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Novel Kinase Inhibitor Identified to Treat Tumor Progression in Cancer

总结
Lead Inventors: Richard T. Ambron, Ph.D.Problem or Unmet Need:Cancer is the second leading cause of mortality in the United States and continues to grow as a major health concern in the developing world. A distinguishing hallmark of cancer is the uncontrollable proliferation and growth of malignant tumor cells. Tumor progression is known to implement complex pathophysiological processes including activation of oncogenes, signaling diverse molecular pathways and angiogenesis, all of which contribute towards the advancement of the cancer. Despite existing treatments and drugs targeting tumor progression, the onset and spread of malignant tumor cells remains a major problem. Development of an effective therapy to inhibit this process remains an active area of research and potential pharmacological agents which effectively targeting tumor progression have immense therapeutic potentials and clinical implications.This technology describes the discovery of a novel inhibitor of a kinase known to mediate tumor progression especially in colorectal cancer, prostate cancer, and multiple myeloma. The kinase targeted, ARK5, is a member of the AMP-activated protein kinase (AMPK) family, which is known to promote tumor cell survival by preventing cell death. Furthermore, ARK5 overexpression has been observed to stimulate tumor cell metastasis and proliferation in colorectal cancer, prostate cancer, and multiple myeloma. This technology describes the first molecular compound halting tumor progression via the ARK5 signaling pathway. This technology also describes the mechanism of inhibition and utilizing this knowledge may give rise to further pharmacologic derivatives of the inhibitor. Thus, this technology presents the discovery of a novel molecular inhibitor of tumor progression and represents the first time a potential therapeutic agent targets the ARK5 pathway.
技术优势
First compound to target the ARK5 mediated pathway of tumor progression Derivatives developed from this compound may give rise to other potential therapeutics Insight acquired about AMPK kinase inhibition can be used to advance research on other kinase inhibitors
技术应用
Treatment of tumor progression in cancer, particularly colorectal and pancreatic cancer and multiple myeloma Allow identification of other AMPK mediated disease pathways as potential targets of therapeutic treatment
详细技术说明
This technology describes the discovery of a novel inhibitor of a kinase known to mediate tumor progression especially in colorectal cancer, prostate cancer, and multiple myeloma. The kinase targeted, ARK5, is a member of the AMP-activated protein ki...
*Abstract
None
*Inquiry
Jerry Kokoshka Columbia Technology Ventures Tel: (212) 854-8444 Email: TechTransfer@columbia.edu
*IR
2549
*Principal Investigation
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备